双鹭药业净利从暴增9倍到突然预亏超2亿，董事长为何自掏5000万补窟窿？

Core Viewpoint - The company, Shuanglu Pharmaceutical, is facing significant financial losses due to investment mismanagement, particularly in wealth management products and trading financial assets, leading to a projected net loss of 290 million to 200 million yuan for the year 2025, marking a year-on-year decline of 170.03% to 291.54% [1][2]. Financial Performance - The company anticipates a net profit attributable to shareholders of -290 million to -200 million yuan for 2025, a drastic decline compared to the previous year [1]. - The net profit after deducting non-recurring gains and losses is expected to be between -70 million to -40 million yuan, reflecting a year-on-year decrease of 148.58% to 185.02% [1]. Investment Losses - The company reported a significant reduction in non-recurring gains and losses, amounting to approximately 200 million yuan, primarily due to confirmed losses from wealth management investments and fair value changes in trading financial assets [2][20]. - Despite the losses, the company holds several stocks that have appreciated in value, suggesting that the trading financial assets may not be the main cause of the projected losses [5][18]. Stock Performance - The company’s holdings in three A-shares have shown positive fair value changes, contributing to a net profit increase of 309.08% in the first half of 2025 [5][6]. - The estimated market value of these stocks at the end of 2025 indicates a floating profit of over 70 million yuan, despite the overall projected losses [8][9]. Wealth Management Products - The company has faced scrutiny over its wealth management products, particularly a 50 billion yuan trust product whose details remain unclear, raising concerns about transparency and risk management [20][21]. - The company has shifted its investment strategy from primarily bank wealth management products to riskier trust products, with a significant portion of its cash reserves being allocated to these investments [20]. Management Actions - The chairman of the company, Xu Mingbo, has voluntarily committed to cover any irrecoverable losses from the wealth management investments, pledging to contribute 50 million yuan within a month [26]. - This commitment is notable as it is rare for a chairman to personally guarantee losses resulting from company investment decisions in the A-share market [26]. Insider Trading Concerns - The company’s secretary, Liang Shujie, executed a rapid share sell-off shortly after the release of the third-quarter report, raising questions about the timing and motivations behind the decision [30][32]. - The sell-off occurred despite a significant increase in net profit reported for the third quarter, suggesting potential insider knowledge of forthcoming negative developments [32][33].